The Food and Drug Administration (FDA) has approved Synjardy XR (empagliflozin and metformin HCl extended-release; Boehringer Ingelheim and Lilly) tablets as an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken.
Synjardy XR combines empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
The FDA approval is supported by data from multiple clinical trials that studied the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea, for the treatment of adults with type 2 diabetes.
Synjardy XR will be available as 5mg/1000mg and 12.5mg/1000mg strength tablets in 60- and 180-count bottles, and as 10mg/1000mg and 25mg/1000mg strength tablets in 30- and 90-count bottles.
For more information call (800) 542-6257 or visit Synjardy.com.